Economic Observation Network The application for the listing of HTD1801, the core product of Junshengtai Pharma-B (02511), has been accepted. The net loss for the first half of 2026 was HKD 167 million, and approximately HKD 222 million was raised through placement.

Product development progress:
The application for marketing of new drug for type 2 diabetes (T2DM) of core product HTD1801 was accepted by the State Food and Drug Administration in March 2026. The approval is in progress, and the company is looking for domestic commercialization partners

The phase III data of HTD1801 combined with metformin in June 2026 were published in NEJM Evidence; In July, domestic experts released a consensus on CKM (cardiovascular kidney metabolism), which is in line with the positioning of HTD1801 as "one drug with multiple effects"

Performance and business situation:
From a fundamental perspective, the company had no operating revenue and a net loss of 167 million yuan in the first half of 2026 (expanding year-on-year), with research and development costs dropping to 36.828 million yuan; The net proceeds from the placement in August amounted to approximately HKD 222 million for commercialization and research and development

The above content is based on publicly available information and does not constitute investment advice.